Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer

Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive inve...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhihui Zhang, Peng Wu, Chaoqi Zhang, Yuejun Luo, Guochao Zhang, Qingpeng Zeng, Lide Wang, Zhaoyang Yang, Nan Sun, Jie He
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	small cell lung cancer antitumor immunity tumor necrosis factor family prognostic prediction chemotherapy response Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/043e68500fe84285a2abee0da4e37ff8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:043e68500fe84285a2abee0da4e37ff8
record_format	dspace
spelling	oai:doaj.org-article:043e68500fe84285a2abee0da4e37ff82021-11-18T09:03:41ZTumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer1664-322410.3389/fimmu.2021.745769https://doaj.org/article/043e68500fe84285a2abee0da4e37ff82021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.745769/fullhttps://doaj.org/toc/1664-3224Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management.Zhihui ZhangPeng WuChaoqi ZhangYuejun LuoGuochao ZhangQingpeng ZengLide WangZhaoyang YangNan SunJie HeFrontiers Media S.A.articlesmall cell lung cancerantitumor immunitytumor necrosis factor familyprognostic predictionchemotherapy responseImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	small cell lung cancer antitumor immunity tumor necrosis factor family prognostic prediction chemotherapy response Immunologic diseases. Allergy RC581-607
spellingShingle	small cell lung cancer antitumor immunity tumor necrosis factor family prognostic prediction chemotherapy response Immunologic diseases. Allergy RC581-607 Zhihui Zhang Peng Wu Chaoqi Zhang Yuejun Luo Guochao Zhang Qingpeng Zeng Lide Wang Zhaoyang Yang Nan Sun Jie He Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
description	Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management.
format	article
author	Zhihui Zhang Peng Wu Chaoqi Zhang Yuejun Luo Guochao Zhang Qingpeng Zeng Lide Wang Zhaoyang Yang Nan Sun Jie He
author_facet	Zhihui Zhang Peng Wu Chaoqi Zhang Yuejun Luo Guochao Zhang Qingpeng Zeng Lide Wang Zhaoyang Yang Nan Sun Jie He
author_sort	Zhihui Zhang
title	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_short	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_full	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_fullStr	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_full_unstemmed	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
title_sort	tumor necrosis factor family member profile predicts prognosis and adjuvant chemotherapy benefit for patients with small-cell lung cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/043e68500fe84285a2abee0da4e37ff8
work_keys_str_mv	AT zhihuizhang tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT pengwu tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT chaoqizhang tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT yuejunluo tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT guochaozhang tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT qingpengzeng tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT lidewang tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT zhaoyangyang tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT nansun tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer AT jiehe tumornecrosisfactorfamilymemberprofilepredictsprognosisandadjuvantchemotherapybenefitforpatientswithsmallcelllungcancer
_version_	1718420943332704256

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer

Ejemplares similares